{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:43:08Z","timestamp":1759466588135,"version":"build-2065373602"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The introduction of enfortumab vedotin combined with pembrolizumab (EV-P) as a first-line treatment for advanced urothelial carcinoma (UC) has transformed the therapeutic landscape and holds great promise for improving patient outcomes. However, predictive and prognostic biomarkers for this novel regimen remain limited, and no specific subgroup has yet been identified for whom frontline EV-P could be withheld in favor of platinum-based chemotherapy. We report the first two cases of patients with BRCA-mutant metastatic UC who experienced markedly short progression-free survival with first-line EV-P but achieved more durable responses with second-line platinum-based chemotherapy. These observations raise important questions about the potential predictive role of BRCA - and more broadly, DNA damage repair - mutations in the evolving treatment paradigm of UC. Given the known sensitivity of BRCA-mutated tumors to platinum agents, frontline platinum-based chemotherapy may warrant consideration in this molecularly defined subgroup. Larger studies are needed to validate these preliminary findings and inform treatment selection.<\/jats:p>","DOI":"10.3389\/fonc.2025.1648230","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:55Z","timestamp":1759464715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation"],"prefix":"10.3389","volume":"15","author":[{"given":"Giuseppe","family":"Salfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Maria Agrippina","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino","family":"Pedrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Tortola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Pereira Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Barizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo","family":"Frattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Graffeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Monni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.1045831","article-title":"The predictors and surgical outcomes of different distant metastases patterns in upper tract urothelial carcinoma: A SEER-based study","volume":"9","author":"Hu","year":"2022","journal-title":"Front Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"B5","volume-title":"Muscle-invasive and Metastatic Bladder Cancer","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumor-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.012","article-title":"A systematic review and meta-analysis of BRCA1\/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer","volume":"66","author":"Jia","year":"2022","journal-title":"Breast"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100019","article-title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","volume":"6","author":"Pellegrino","year":"2021","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1038\/s41598-017-04897-x","article-title":"Mutations in BRCA2 and taxane resistance in prostate cancer","volume":"7","author":"Nientiedt","year":"2017","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.1079","article-title":"Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations","volume":"26","author":"Wysocki","year":"2008","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.016","article-title":"Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer","volume":"49","author":"Tan","year":"2013","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/23523735251317865","article-title":"Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC)\u00a0payloads in bladder cancer","volume":"11","author":"Shanmugam S","year":"2025","journal-title":"Bladder Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2400938","DOI":"10.1200\/PO-24-00938","article-title":"Relationship among DNA damage response gene alterations, molecular subtypes, and survival outcomes in patients with metastatic bladder cancer treated on CALGB 90601","volume":"9","author":"Iyer","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicenter, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic\u00a0biomarkers associated with enfortumab vedotin outcomes for patients with advanced urothelial carcinoma: analysis of UNITE study data","volume":"8","author":"Jindal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.03.005","article-title":"Front-line platinum continues to have a role in advanced bladder cancer","volume":"10","author":"Vogl","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.36000\/HBT.OH.2025.24.184","article-title":"Current advances in the perioperative treatment of muscle-invasive bladder cancer","volume":"24","author":"Vogl","year":"2025","journal-title":"Healthbook TIMES Oncol Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS585","article-title":"Phase 3 KEYNOTE-905\/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","article-title":"A\u00a0phase 3, randomized, open-label, multicenter, global study of the efficacy and\u00a0safety\u00a0of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D\u00a0+ EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder\u00a0cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","article-title":"KEYNOTE-B15\/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)","volume":"39","author":"Hoimes","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1648230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:56Z","timestamp":1759464716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1648230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1648230"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1648230","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1648230"}}